Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910307 | 1.00 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MAPTLMNAKMT2A | |
| SCHEMBL4909540 | 0.83 | KMT2A (0.62) | ALDH1A1SMN1; SMN2MAPTLMNAKMT2A | |
| SCHEMBL4909547 | 0.83 | KMT2A (0.62) | ALDH1A1SMN1; SMN2MAPTLMNAKMT2A | |
| SCHEMBL11564387 | 0.81 | AKR1C3 (0.48) | ALDH1A1SMN1; SMN2KMT2ARAB9AMEN1 | |
| SCHEMBL11564392 | 0.81 | AKR1C3 (0.48) | ALDH1A1SMN1; SMN2KMT2ARAB9AMEN1 | |
| SCHEMBL28389546 | 0.81 | AKR1C3 (0.47) | ALDH1A1SMN1; SMN2KMT2AMEN1AKR1C3 | |
| SCHEMBL28391526 | 0.81 | AKR1C3 (0.47) | ALDH1A1SMN1; SMN2KMT2AMEN1AKR1C3 | |
| SCHEMBL4901429 | 0.80 | KMT2A (0.58) | ALDH1A1SMN1; SMN2MAPTLMNAKMT2A | |
| SCHEMBL4901427 | 0.80 | KMT2A (0.58) | ALDH1A1SMN1; SMN2MAPTLMNAKMT2A | |
| SCHEMBL556702 | 0.79 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2MAPTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791901-B1 | STABILIZATION OF ORGANIC MATERIALS | BASF SE (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-9051448-B2 | Stabilization of organic materials | BASF SE (DE) | 2015-06-09 | — | — | US | disclosed |
| US-20080269382-A1 | Stabilization of Organic Materials | BASF SE (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1791901-A2 | STABILIZATION OF ORGANIC MATERIALS | Ciba SC Holding AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006024611-A2 | STABILIZATION OF ORGANIC MATERIALS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269382-A1 | Stabilization of Organic Materials | LPO, PPOX, HMOX1 | ALDH1A1 129/4885SMN1; SMN2 954/4885MAPT 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.